Transiderm-Nitro 5 milligrams/24 hours Transdermal Patch

  • Name:

    Transiderm-Nitro 5 milligrams/24 hours Transdermal Patch

  • Company:
    info
  • Active Ingredients:

    Glyceryl Trinitrate

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 19/09/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/7/2018

Click on this link to Download PDF directly

Novartis Ireland Limited

Novartis Ireland Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Aclasta 5 mg solution for infusion Active Ingredients Zoledronic acid monohydrate
Medicine Name Afinitor Tablets Active Ingredients Everolimus
Medicine Name Aimovig Active Ingredients Erenumab
Medicine Name Atriance 5 mg/ml solution for infusion Active Ingredients Nelarabine
Medicine Name Azarga 10mg/ml + 5mg/ml eye drops, suspension Active Ingredients Brinzolamide, Timolol Maleate
Medicine Name Azopt 10mg/ml eye drops suspension Active Ingredients Brinzolamide
Medicine Name Cataflam 50 mg Coated Tablets Active Ingredients Diclofenac Potassium
Medicine Name Certican Tablets Active Ingredients Everolimus
Medicine Name CILOXAN 3 mg/ml ear drops, solution Active Ingredients Ciprofloxacin hydrochloride
Medicine Name Co-Diovan 160 mg/12.5 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 160mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 320mg/25mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Co-Diovan 80mg/12.5mg film-coated tablets Active Ingredients Hydrochlorothiazide, Valsartan
Medicine Name Cosentyx 150 mg solution for injection in pre-filled pen Active Ingredients secukinumab
Medicine Name Desferal 500mg Vials Active Ingredients Desferrioxamine Mesylate
Medicine Name Diovan 160 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 320mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 3mg/ml Oral Solution Active Ingredients Valsartan
Medicine Name Diovan 40 mg film-coated tablets Active Ingredients Valsartan
Medicine Name Diovan 80 mg film-coated tablets Active Ingredients Valsartan
Medicine Name DuoTrav Eye Drops Solution Active Ingredients Timolol Maleate, Travoprost
Medicine Name Entresto 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets Active Ingredients Sacubitril, Valsartan
Medicine Name Estradot Transdermal Patches Active Ingredients Estradiol Hemihydrate
Medicine Name Eucreas 50mg / 850mg and 50mg / 1000mg film-coated tablets Active Ingredients Metformin Hydrochloride, Vildagliptin
1 - 0 of 116 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 19 September 2019 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 19 September 2019 PIL

Reasons for updating

  • Improved presentation of PIL

Updated on 29 August 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - manufacturer

Updated on 18 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 18 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 16 September 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 16 September 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 28 July 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change IMB to HPRA

Updated on 28 July 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 27 June 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 20 March 2013 PIL

Reasons for updating

  • Change of contraindications

Updated on 12 March 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

1.       Inclusion the following contraindications in Section 4.3:

·         Severe hypotension (systolic blood pressure less than 90mmHg)

·         Severe hypovolaemia

2.       Addition of the following text on hypoxaemia to ‘Precautions’ in section 4.4:

Updated on 24 May 2012 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

·         Section 4.8: Addition of “palpitation” and “rash generalized” as post-marketing ADR

·         Section 5.1, 5.2 and 5.3: Addition of pharmacological, pharmacokinetic and pre-clinical data

Updated on 22 May 2012 PIL

Reasons for updating

  • Change to information about driving or using machinery
  • Change due to user-testing of patient information

Updated on 18 January 2012 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.4:

Rewording

Addition of “Removal of the patch should be considered as part of the management of patients who develop significant hypotension.”

Removal of the precaution in patient with closed angle glaucoma.

Addition precaution in patients with G6PD deficiency induced anaemia

 

Section 4.5 Addition of “Concurrent administration of Transiderm Nitro with amifostine and acetyl salicyclic acid may potentiate the blood lowering effects of Transiderm Nitro.”

 

Section 4.6: Rewording

 

Section 4.7: Rewording

 

Section 4.8: Correction of typoographical error

 

Section 4.9: Rewording

 

 

Updated on 11 May 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 1: Change in product name from Transiderm Nitro 5mg/24hrs to Transiderm Nitro 5milligrams/24hours
Section 6.6: More detailed disposal instructions added: "The patch should not be used if the seal is broken. When changing the patch, the used patch should be removed, the adhesive layer folded inwards on itself and the patch disposed of safely and out of reach and sight of children. Any used or unused patches should be discarded according to local requirements or returned to the pharmacy"

Updated on 28 April 2010 PIL

Reasons for updating

  • Change of trade or active ingredient name

Updated on 17 July 2007 PIL

Reasons for updating

  • Change of trade or active ingredient name

Updated on 12 July 2007 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Name changed from Transiderm -Nitro 5 Patch to Transiderm-Nitro 5mg/24hr Transidermal Patch

Updated on 8 February 2006 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 10 October 2005 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 20 June 2005 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 9 May 2005 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 May 2005 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
  • Change of contraindications
  • Change to date of revision
  • Change to side-effects
  • Change to drug interactions

Updated on 26 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie